Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Xeris Pharmaceuticals Inc (XERS)

Xeris Pharmaceuticals Inc (XERS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 250,006
  • Shares Outstanding, K 140,453
  • Annual Sales, $ 163,910 K
  • Annual Income, $ -62,260 K
  • 60-Month Beta 2.33
  • Price/Sales 1.54
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade XERS with:

Options Overview Details

View History
  • Implied Volatility 75.93% ( -50.34%)
  • Historical Volatility 43.01%
  • IV Percentile 24%
  • IV Rank 10.52%
  • IV High 534.22% on 10/31/23
  • IV Low 22.07% on 03/27/24
  • Put/Call Vol Ratio 0.02
  • Today's Volume 813
  • Volume Avg (30-Day) 244
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 15,702
  • Open Int (30-Day) 13,882

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.12
  • Number of Estimates 5
  • High Estimate -0.11
  • Low Estimate -0.14
  • Prior Year -0.12
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7300 +1.73%
on 04/18/24
2.2799 -22.80%
on 03/28/24
-0.3700 (-17.37%)
since 03/18/24
3-Month
1.7300 +1.73%
on 04/18/24
3.2600 -46.01%
on 02/15/24
-0.7200 (-29.03%)
since 01/18/24
52-Week
1.4600 +20.55%
on 11/15/23
3.2600 -46.01%
on 02/15/24
-0.5600 (-24.14%)
since 04/18/23

Most Recent Stories

More News
Ocular Therapeutix (OCUL) Reports Q1 Loss, Lags Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -14.81% and 4.62%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

OCUL : 5.86 (-22.69%)
XERS : 1.7600 (-1.12%)
Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range...

XERS : 1.7600 (-1.12%)
Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSolâ„¢ Formulations

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range...

XERS : 1.7600 (-1.12%)
Xeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regeneron for XeriJectâ„¢

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapeutic...

XERS : 1.7600 (-1.12%)
Xeris Biopharma Appoints Ricki Fairley to Board of Directors

Xeris Biopharma Holdings (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapeutic...

XERS : 1.7600 (-1.12%)
Xeris Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range...

XERS : 1.7600 (-1.12%)
Xeris Biopharma to Report Fourth Quarter and Full-Year 2022 Financial Results on March 8, 2023

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range...

XERS : 1.7600 (-1.12%)
Xeris Biopharma to Participate in the SVB Securities Global Biopharma Conference 2023

Xeris Biopharma, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies,...

XERS : 1.7600 (-1.12%)
Xeris Biopharma Announces FDA Grants Orphan-drug Exclusivity for Recorlev®

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies,...

XERS : 1.7600 (-1.12%)
Xeris Biopharma to Present at 41st Annual J.P. Morgan Healthcare Conference

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range...

XERS : 1.7600 (-1.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Xeris Biopharma Holdings is a biopharmaceutical company. It involved in developing and commercializing therapies for patient in endocrinology, neurology and gastroenterology. The company's principal product includes Gvoke(R), a ready-to-use liquid glucagon for the treatment of severe hypoglycemia and...

See More

Key Turning Points

3rd Resistance Point 1.8667
2nd Resistance Point 1.8333
1st Resistance Point 1.7967
Last Price 1.7600
1st Support Level 1.7267
2nd Support Level 1.6933
3rd Support Level 1.6567

See More

52-Week High 3.2600
Fibonacci 61.8% 2.5724
Fibonacci 50% 2.3600
Fibonacci 38.2% 2.1476
Last Price 1.7600
52-Week Low 1.4600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar